We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Henry Schein's (HSIC) New Buyout Expands Its Switzerland Base
Read MoreHide Full Article
Henry Schein, Inc. (HSIC - Free Report) recently acquired 100% stake in Switzerland-based Condor Dental Research Company SA. Upon closing of the transaction, Condor Dental has joined Henry Schein’s International Distribution Group.
Financial terms of the deal were not disclosed. However, this buyout is estimated to be neutral to Henry Schein’s diluted earnings per share in 2022 and accretive thereafter
Few Words on Condor Dental
Condor Dental has been acquired by Henry Schein from MCCB Holding Sarl — a health care holding company wholly owned by the Libon family.
Founded in 1978 and based in Vouvry, Switzerland, Condor Dental, a privately-held dental distribution company, serves general dental practitioners, specialists and laboratories.
The company reported around $18 million in sales for 2021. The majority of the sales were derived from dental consumable merchandise, with additional revenues from the customization of dental practices and dental laboratory installations.
Strategic Implications of the Deal
This acquisition underscores Henry Schein’s long-standing commitment to strategic acquisitions that allows it to serve customers better while expanding its vast range of products and services that supports high-quality dental care delivery.
Henry Schein has served the Swiss dental implant market through its Basel-based division, Camlog Biotechnologies GmbH, since 2004. The latest acquisition of Condor Dental further extends the company’s foray into the Swiss market for its dental distribution business.
Image Source: Zacks Investment Research
Per management, Henry Schein’s operational expertise will strengthen Condor Dental’s market position and enhance the level of services and solutions delivered to dental practitioners.
Condor Dental offers considerable growth opportunities within one of Europe’s most promising dental markets. The latest acquisition translates into a significant opportunity for Henry Schein to grow its footprint in Switzerland and to provide the Swiss dental community with its comprehensive portfolio of technology and value-added solutions.
Industry Prospects
Per a report by Fortune Business Insights, the global dental market is expected to see a CAGR of 7.4% during 2022-2029. Factors such as the growing prevalence of dental ailments and increasing technological advancements can be attributable to market growth.
Given the substantial market prospects, Henry Schein’s latest buyout to expand its presence in the Swiss market seems well-timed.
Recent Developments
In the first quarter of 2022, Henry Schein registered robust performance within its dental business, attributable to strong global equipment and consumable merchandise sales. Global dental sales increased 2.2% compared with the same period last year. The company noted that growth was strong in each dental specialty category, including implants, oral surgery, endodontics and orthodontics.
Apart from this, the Henry Schein One dental software business continued to progress well despite a challenging business environment. Growth within Henry Schein One continues to be driven by a recovery in in-patient traffic to dental offices.
In March 2022, Henry Schein One introduced a version of its dental analytics platform for dental service organization (DSO) — Jarvis Analytics — to help private dental practices accelerate business growth. The latest development will support Henry Schein’s objective to provide the best-quality solutions to dental practices.
Share Price Performance
The stock has outperformed its industryin the past year. The stock has dropped 0.1% compared to the industry's 10.5% decline.
Zacks Rank and Key Picks
Currently, Henry Schein carries a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical space that investors can consider are AMN Healthcare Services, Inc. (AMN - Free Report) , Novo Nordisk (NVO - Free Report) and Merck & Co., Inc. (MRK - Free Report) .
AMN Healthcare has a long-term earnings growth rate of 1.1%. The company surpassed the Zacks Consensus Estimate for its earnings in the trailing four quarters, delivering a surprise of 15.6%, on average. It currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
AMN Healthcare has outperformed its industry in the past year. AMN has gained 13.6% against the industry’s 12.5% fall.
Novo Nordisk has a long-term earnings growth rate of 15.6%. The company surpassed earnings estimates in the trailing four quarters, delivering a surprise of 7.6%, on average. It currently carries a Zacks Rank #2.
Novo Nordisk has outperformed its industry in the past year. NVO has gained 27% against the industry’s 16.3% growth.
Merck has a long-term earnings growth rate of 10.1%. The company surpassed earnings estimates in the trailing three quarters and missed in one, delivering a surprise of 13.4%, on average. It currently carries a Zacks Rank #2.
Merck has outperformed its industry in the past year. MRK has gained 19.3% against the industry’s 16.3% growth.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Henry Schein's (HSIC) New Buyout Expands Its Switzerland Base
Henry Schein, Inc. (HSIC - Free Report) recently acquired 100% stake in Switzerland-based Condor Dental Research Company SA. Upon closing of the transaction, Condor Dental has joined Henry Schein’s International Distribution Group.
Financial terms of the deal were not disclosed. However, this buyout is estimated to be neutral to Henry Schein’s diluted earnings per share in 2022 and accretive thereafter
Few Words on Condor Dental
Condor Dental has been acquired by Henry Schein from MCCB Holding Sarl — a health care holding company wholly owned by the Libon family.
Founded in 1978 and based in Vouvry, Switzerland, Condor Dental, a privately-held dental distribution company, serves general dental practitioners, specialists and laboratories.
The company reported around $18 million in sales for 2021. The majority of the sales were derived from dental consumable merchandise, with additional revenues from the customization of dental practices and dental laboratory installations.
Strategic Implications of the Deal
This acquisition underscores Henry Schein’s long-standing commitment to strategic acquisitions that allows it to serve customers better while expanding its vast range of products and services that supports high-quality dental care delivery.
Henry Schein has served the Swiss dental implant market through its Basel-based division, Camlog Biotechnologies GmbH, since 2004. The latest acquisition of Condor Dental further extends the company’s foray into the Swiss market for its dental distribution business.
Image Source: Zacks Investment Research
Per management, Henry Schein’s operational expertise will strengthen Condor Dental’s market position and enhance the level of services and solutions delivered to dental practitioners.
Condor Dental offers considerable growth opportunities within one of Europe’s most promising dental markets. The latest acquisition translates into a significant opportunity for Henry Schein to grow its footprint in Switzerland and to provide the Swiss dental community with its comprehensive portfolio of technology and value-added solutions.
Industry Prospects
Per a report by Fortune Business Insights, the global dental market is expected to see a CAGR of 7.4% during 2022-2029. Factors such as the growing prevalence of dental ailments and increasing technological advancements can be attributable to market growth.
Given the substantial market prospects, Henry Schein’s latest buyout to expand its presence in the Swiss market seems well-timed.
Recent Developments
In the first quarter of 2022, Henry Schein registered robust performance within its dental business, attributable to strong global equipment and consumable merchandise sales. Global dental sales increased 2.2% compared with the same period last year. The company noted that growth was strong in each dental specialty category, including implants, oral surgery, endodontics and orthodontics.
Apart from this, the Henry Schein One dental software business continued to progress well despite a challenging business environment. Growth within Henry Schein One continues to be driven by a recovery in in-patient traffic to dental offices.
In March 2022, Henry Schein One introduced a version of its dental analytics platform for dental service organization (DSO) — Jarvis Analytics — to help private dental practices accelerate business growth. The latest development will support Henry Schein’s objective to provide the best-quality solutions to dental practices.
Share Price Performance
The stock has outperformed its industryin the past year. The stock has dropped 0.1% compared to the industry's 10.5% decline.
Zacks Rank and Key Picks
Currently, Henry Schein carries a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical space that investors can consider are AMN Healthcare Services, Inc. (AMN - Free Report) , Novo Nordisk (NVO - Free Report) and Merck & Co., Inc. (MRK - Free Report) .
AMN Healthcare has a long-term earnings growth rate of 1.1%. The company surpassed the Zacks Consensus Estimate for its earnings in the trailing four quarters, delivering a surprise of 15.6%, on average. It currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
AMN Healthcare has outperformed its industry in the past year. AMN has gained 13.6% against the industry’s 12.5% fall.
Novo Nordisk has a long-term earnings growth rate of 15.6%. The company surpassed earnings estimates in the trailing four quarters, delivering a surprise of 7.6%, on average. It currently carries a Zacks Rank #2.
Novo Nordisk has outperformed its industry in the past year. NVO has gained 27% against the industry’s 16.3% growth.
Merck has a long-term earnings growth rate of 10.1%. The company surpassed earnings estimates in the trailing three quarters and missed in one, delivering a surprise of 13.4%, on average. It currently carries a Zacks Rank #2.
Merck has outperformed its industry in the past year. MRK has gained 19.3% against the industry’s 16.3% growth.